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Generic prescribing for epilepsy remains controversial. This study aimed to ascertain if a change occurred in the 
incidence of seizures or side-effects when a different pharmaceutical manufacturer's version of the same 
antiepileptic drug was taken (a 'switch'). 
Forty general practices with a list size of 350 168 were recruited. They identified 2285 people being treated for 
epilepsy with either carbamazepine, phenytoin or sodium valproate. 
A questionnaire was sent to the people with epilepsy. Those who recalled taking a different pharmaceutical 
manufacturer's supply of the same antiepileptic drug over the last 2 years were interviewed by their practice if they 
reported a problem with the control of their epilepsy after a 'switch'. 
One thousand, three hundred and thirty-three (58.8%) people with epilepsy responded: 251 (18.7%) had 
experienced a 'switch', 27 (10.8%) reported "validated' problems; 25 (9.9%) reported unproven problems: 22 
(8.8%) reported problems, but follow-up was incomplete: 177 (70.5%) reported no problems. 
This study suggests that money saved by generic prescribing is outweighed by negative health gain for the person 
with epilepsy, increased work in general practice, and increased social costs. 
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INTRODUCTION 
In 1987 the Drug and Therapeutics Bulletin t
recommended 'that prescribers hould, wherever 
possible, use generic names rather than brand 
ones.' Should antiepileptic drugs be an 
exception? 
Following the introduction of practice drug 
budgets and the development of formularies in 
hospitals and practices, the generic prescribing of 
antiepileptic drugs (AEDs) has doubled in the 
past 5 years 2. 
Doubts about the safety of generic prescribing 
for epilepsy arose in 1968 following reports of 
an outbreak of phenytoin intoxication among 
patients with epilepsy who had received the drug 
from a different source of manufacture 3. 
Evidence for the safety of generic prescribing 
for epilepsy is not conclusive. Reports from 
controlled studies are conflicting 4-~2. A British 
Epilepsy Association survey found that 60 
(46.5%) people perceived a worsening of their 
condition after receiving a different supply 
('switch') of the same AED 13. 
The Food & Drug Administration (FDA) allow 
a plus or minus 20% difference in bioavailability 
when licensing generics compared with the 
branded drug H and the European guidelines, 
although tighter, allow a similar laxity ~s. This is 
probably acceptable for most drugs, but there are 
fears for AEDs where small changes in bioavaila- 
bility may result in poorer control of seizures with 
consequent serious implications for the person's 
quality of life t6. 
With this conflicting evidence it is not surpris- 
ing that expert recommendations vary. 
In the USA, Nuwer et a117 stated 'while generic 
medications offer the potential for significant cost 
reduction, short-term economic considerations 
should not be allowed to jeopardize the health of 
persons with epilepsy. Doing so may actually 
increase health care costs in addition to adversely 
affecting quality of life.' But Young 18, on behalf 
of the FDA said 'at present here is no credible 
evidence that the use of agency-approved generic 
antiepileptics results in an increased frequency of 
seizures.' The Medicines Resource Centre 
(MeReC) ~9, the American Academy of 
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Neurology 2° and the New Zealand Medical 
Association 21 have warned against switching 
between branded and generic forms of AED. As 
yet, the Medicines Control Agency (UK) do not, 
but the Audit Commission (UK) do 22. 
Methodologies for investigating this issue are 
extremely difficult. Controlled double-blind, 
crossover studies in the community cannot be 
justified, because of the high incidence of 
anecdotal adverse xperiences. Innovative meth- 
ods have therefore to be used. Given that large 
numbers of people have already had their AED, 
'switched', their experiences can only be analysed 
retrospectively. 
We wanted to see if we could provide evidence 
that may enable health decision makers to reach 
sensible conclusions on this issue. 
The aim of the study was to ascertain whether 
there is a change in the incidence of seizures and 
side-effects when 'switching' between different 
suppliers of the same AED. 
METHODS 
General practices in the Yorkshire Health Region 
of three or more partners were approached to 
ascertain whether or not they would participate in
the study. 
A patient questionnaire and introductory let- 
ters were designed and piloted (available from 
the authors). After a visit from a study team 
member, recruited practices ent these to people 
who were identified from repeat prescription 
systems and/or a disease register as taking 
carbamazepine, phenytoin or sodium valproate 
for epilepsy. These three drugs were chosen 
because they are prescribed frequently and are 
available as generics. A reply paid envelope, 
addressed to each practice was provided for each 
patient contacted. Practices were reimbursed for 
their administration costs. 
Every person who recalled taking a different 
supply of the same AED over the last 2 years was 
followed up by their practice if they reported a 
problem with the control of their epilepsy after a 
'switch'. The person's GP discussed their per- 
ceived problems and whether any other reason 
except he 'switch' in supplies of their AED could 
be identified. 
After each discussion people reporting prob- 
lems were allocated to the following groups: 
(1) 'switch' problems 'validated'---increase in 
seizure frequency or side-effects with no other 
identifiable medical or psychological cause. 
(2) 'switch' problems unproven--increase in 
seizure frequency or side-effects where other 
likely medical or psychological explanations were 
identified. 
(3) follow-up incomplete--increase in seizure 
frequency or side-effects, but the person did not 
respond to follow-up approaches or opted for no 
further contact on the questionnaire. 
People who had not taken a different supply of 
their AED in the last 2 years or did not report 
problems after a 'switch' where not contacted 
again. 




Five hundred and fifty-six practices were con- 
tacted; 155 (27.9%) replied, of which 57 (10.3%) 
agreed to participate. Resources allowed 40 to be 
recruited on a 'first come, first served' basis. 
Participating practices were from a variety of 
geographical locations and varied in size from 
4100 to 20 000 patients. Their total list size was 
350 168. 
People being treated for epilepsy 
A total of 2285 people were contacted (0.65% of 
the population studied) and asked to complete 
the questionnaire. In all, 1343 (58.8%) replied, of 
which 49.9% were male and 50.1% were female. 
Their mean age was 45.79 with a range of 1-94 
(sd, 20.80). The mean age of onset for their 
epilepsy was 29.88 with a range of 0-90 (sd, 
24.57). Mean seizure frequency was 7.31 per 
month with a range of 0-600 per month (sd, 
35.77). 
Attitude to drug therapy (n = 1288, lower figure 
due to missing answers on questionnaire) 
It was found that 74.5% take a close interest in 
their medication, 7.1% never query variations in 
the presentation f their drugs, but changes make 
them anxious, 11.9% never query variations and 
changes do not worry them and 6.5% do not pay 
close attention to the presentation of their drugs 
and would not have noticed variations. 
Generic prescribing for epilepsy 
Table 1: Version of antiepileptic drug being taken 
Version of antiepileptic drug Percentage 
Sv 
Epilim 83.2% 
Epilim Chrono 2.5% 
Orlept 1.1% 
Unbranded sodium valproate 13.2% 
Cbz 
Tegretol 44.2% 
Tegreto! Retard 11.8% 
Epimax 5.6% 
Unbranded carbamazepine 38.4% 
Phy 
Epanutin 60.8% 
Unbranded phenytoin 39.2% 
Experiences of people reporting a 'validated' 
problem 
A 'validated' problem after a 'switch' was 
reported by 27 patients (10.8%). Table 3 de- 
scribes the types of problem. 
Types of 'switches' for 'validated' problems 
(n = 27) 
Problems were seen when 'switching' from a 
branded product to a generic product (68%), 
generic to brand (12%) and between generics 
(20%). 
Antiepileptic drugs (n = 1324) 
Of the patients, 37.8% reported presently taking 
carbamazepine, 39.2% sodium valproate and 
32.6% phenytoin. (Percentages total greater than 
100% because of polytherapy.) The version of 
these drugs being presently taken is outlined in 
Table 1: 73.9% were taking monotherapy; 22.1% 
were taking two drugs; 3.6% were taking three; 
0.4% were taking four or more. 
Seizure frequency and side-effects on present 
medication (n = 1343) 
Of the overall sample, 45.3% were seizure-free 
with no side-effects, 12.6% were seizure free, but 
reported side-effects, 26.3% considered their 
epilepsy to be well-controlled even though they 
still had seizures and 15.8% viewed their epilepsy 
to be poorly-controlled. 
People's experiences after 'switching' in the last 
2 years 
A total of 251 (18.7%) had experienced a 'switch'. 
Table 2 shows their experiences. The categories 
are explained in the methodology. 
Characteristics of the people who reported 
problems and those who did not 
Table 4 compares the characteristics of people 
who reported problems, 'validated' or not, with 
those reporting no problems. 
DISCUSSION 
Recruitment was easier than expected, suggesting 
that general practices were concerned, interested 
and welcomed further guidance on this issue. 
However, covering the administration costs for 
practices could have been a possible factor 
affecting response rate. 
Table 3: Types of validated problem 
Sv Cbz Phy Total 
Number of validated 
problems 13 10 4 27 
First seizure for over 12 
months 1 0 0 1 
Increase seizure frequency 3 5 0 8 
Felt worse/side-effects 9 8 4 21 
SV, Sodium valproate: Cbz, carbamazepine; Phy, phenytoin. 
NB: Totals for experiences are greater than 27 due to some 
people reporting both an increase in seizures and feeling 
worse/side-effects. 
Table 2: Experience after a 'switch' 
Sv Cbz Phy Total 
n(%) n(%) n(%) n(%) 
Number of switches 100 94 57 251 (18.7°1o) 
Categories 
Validated problems 13 (13.0%) 10 (10.6%) 4 (7.0%) 27 (10.8%) 
Unproven problems 12 (12.0%) 8 (8.5%) 5 (8.8%) 25 (9.9%) 
Problems, follow- 
up incomplete 5 (5.0%) 9 (9.6%) 8 (14.0%) 22 (8.8%) 
No problems 70 (70.0%) 67 (71.3%) 40 (70.2%) 177 (70.5%) 
Sv, Sodium valproate; Cbz, carbamazepine; Phy, phenytoin. 
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Table 4: Characteristics of the people who reported problems and those who did not 
None Switch problems Follow-up 
n = 177 incomplete 
unproven validated n = 22 
n = 25 n = 27 
Age: 
Mean 41.53 46.05 39.04 44.06 
sd 18.68 22.81 18.03 15.35 
Sex: 
Male 49.0% 36.8% 33.3% 44.4% 
Female 51.0% 63.2% 66.7% 55.6% 
Age onset epilepsy: 
Mean 25.52 32.95 26.00 30.22 
sd 21.53 25.51 22.99 18.35 
Seizure frequency: 
Mean 3.06/mth 11.28/mth 1.25/mth 4.23/mth 
sd 5.80 29.62 1.37 7.20 
Attitude to drug therapy: 
Takes close interest 59.4% 57.9% 85.2% 77.8%* 
Never query/anxious 13.3% 21.1% 11.1% 11.1% 
Never query/no worries 20.3% 21.1% 3.7% 11.1% 
Does not pay close attention 7.0% 0.0% 0.0% 0.0% 
Number of medications: 
One 69.4% 73.7% 85.2% 77.8% 
Two 25.2% 21.1% 14.8% 16.7% 
Three 4.8% 5.3% 0.0% 5.6% 
Four 0.7% 0.0% 0.0% 0.0% 
* The only significant difference is in 'Attitude to drug therapy' (Chi-squared =9.29. P < 0.03) 
Although retrospective, this study has thoro- 
ughly investigated people's perceptions of the 
effects of a 'switch' of antiepileptic medication. It
used a broadly-based general practice population, 
lending greater weight to this study than pre- 
viously published work. The proportion of the 
population studied found to have epilepsy was 
similar to other recent studies 23. Responders were 
similar in sex, seizure frequency and number of 
drugs taken to the same studies 23. 
After 'switching', 177 patients (70.5%) ex- 
perienced no problems. This could support the 
argument for generic prescribing of AEDs. 
However a sizeable minority of 74 (29.5%) 
reported perceived problems after a 'switch'. 
Factors other than differences in bioavailability 
could have led to people reporting problems, for 
example stress, worry, confusion due to changing 
pill size and colour, attribution bias and poor 
dispensing. But in 27 (10.8%), the person's GP 
shared their belief that the 'switch' was the 
principal cause. 
People who reported 'validated' problems 
could not be differentiated significantly from 
those reporting no problems in terms of seizure 
frequency or number of medications taken. The 
only significant difference was in attitude towards 
drug therapy with those who reported 'validated' 
problems taking a closer interest. This suggests 
the disease pattern for those reporting 'validated' 
problems is no different from those reporting no 
problems, but that people who take a close 
interest in their medication are more likely to 
report problems. 
All three most-commonly prescribed AEDs 
were associated with 'validated' problems result- 
ing from 'switches'. This challenges the theory 
that drugs with a narrow therapeutic window 
(such as phenytoin) are more likely to cause 
problems after 'switches', than those without, like 
sodium valproate ~7. 'Validated' problems oc- 
curred when 'switching' between generic prod- 
ucts, generic to brand and brand to generic, 
suggesting any 'switch' rather than a quality 
problem with a particular supply is the concern. 
Approximately 360000 people are being 
treated for epilepsy 23. If all 'switched' supplies of 
their antiepileptic medication this study suggests 
that approximately 39 000 would suffer 'validated' 
problems and 106000 would perceive some 
problems. What are the health and economic 
costs? 
Generic prescribing decreases drug costs 19, 
although presently, for AEDs the margin bet- 
ween generic and proprietary drugs is tiny, 
representing little opportunity for savings 24. 
However, generic prescribing for epilepsy may 
increase other costs. 
Practices are likely to experience a rise in 
consultations and enquiries from people after a 
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'switch'. Accurate costs for this increased work 
are difficult to measure, but Jumao-as et al in the 
USA 4 found this additional cost averaged $140 
(£93.00) per patient, per annum. 
Problems resulting from a 'switch', especially 
increased seizure frequency or side-effects, could 
increase social costs through increased sick leave, 
loss of employment and other welfare benefits. 
CONCLUSIONS 
This study supports the argument against generic 
prescribing for epilepsy. It suggests that the small 
amount of money saved by generic prescribing is 
outweighed by negative health gain for the person 
with epilepsy, increased work in general practice, 
and increased social costs. 
Epilepsy is unique in its potential adverse 
psycho-social implications. Generic prescribing 
may make such consequences more likely. 
Unless the safety of generic prescribing for 
epilepsy can be more strongly substantiated 
should the Department of Health continue to 
advocate this policy? 
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